By James Gallagher ; A new drug is the "most effective" treatment for relapsing-remitting multiple sclerosis, say UK researchers. ; During MS the body's immune system turns on its own nerves causing debilitating muscle problems. ; Researchers at the University of Cambridge say a cancer drug, which wipes out and resets the immune system, has better results than other options.
There are special rules for certain rare diseases ("orphan diseases") in several major drug... states (MS), the outcome of assessments differs significantly across the EU[6] with...
for MS that requires a refrigerated chain of distribution and costs $17,000 a year.[1] Some... [4] In 1991 the FDA approved the first version of Genzyme's orphan drug alglucerase, the only...
nature biotechnology volume 31 NumBeR 5 mAY 2013 373 Third oral MS drug wins FDA nod Biogen... the Genzyme unit of Paris-based Sanofi, received a refusal-to-file letter last year. Although...
Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a study o...
[41] This has shown brain atrophy reduction in secondary progressive MS.[41] This drug is under research for PPMS and SPMS in phase III. [42] Phase II [edit] Phase II studies are performed...
/CNW/ - Sanofi Genzyme is pleased to announce that the Government of Saskatchewan has added LEMTRADA® (alemtuzumab) to the province's MS Drugs Program for...
Genzyme Inc. said today the U.S. Food and Drug Administration has accepted for review the Cambridge-based company’s application seeking approval of Lemtrada to treat relapsing multiple sclerosis.Th...
sclerosis (MS) drugs, Sanofi’s (Genzyme) alemtuzumab (Lemtrada) and Biogen Idec’s BG-12... Approval for another Sanofi drug, teriflunomide (Aubagio), could come even earlier (Box 1)...
market in a few weeks, a spokeswoman for Sanofi unit Genzyme said. Multiple sclerosis, which... injectable drug for MS. In addition to Aubagio, Sanofi has filed for approval for MS...